drugset

drugset / Trial / NCT00062478

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

NCT00062478 ↗

Phase 2 Completed 40 enrolled BioNumerik Pharmaceuticals, Inc. Crown Bioscience · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.

Timeline

Start: 2001-10
Primary completion: 2002-08
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cositecan	Small molecule	1 mg/m2	Intravenous

Indications